July 11, 2024
Long-term pharmacotherapy for obesity and overweight
Lean body mass remained statistically unchanged
Metabolic Adaptation (Your Body Fights Back) After several weeks in a caloric deficit, your body makes adjustments: Resting metabolic rate drops the body reduces energy expenditure to defend its fat stores Adaptive thermogenesis non-exercise activity (fidgeting, posture, unconscious movement) decreases Leptin levels fall as fat mass drops, leptin (the satiety signal) decreases, which can increase hunger at the margin Retatrutide's triple agonism (GLP-1, GIP, glucagon) helps counter this better than semaglutide or tirzepatide alone the glucagon component specifically boosts resting metabolic rate and fat oxidation
The rax1-1 mutant is characterized by an enhanced APX2 gene expression due to a lesion in the gene encoding GSH1 concomitantly with a 50% reduced GSH content
The catalog covers popular research and GLP-1 peptides including tirzepatide, semaglutide, retatrutide, cagrilintide, survodutide, BPC-157, TB-500, ipamorelin, CJC-1295, sermorelin, tesamorelin, melanotan II, PT-141 and GHK-Cu, with more added as references are verified
